Key Highlights
- Zenkuda successfully achieved primary endpoint in GLOW2 Phase 3 clinical trial for diabetic retinopathy
- Treatment group showed 62.5% response rate compared to only 3.3% in control group
- The therapy demonstrated an 85% reduction in risk for vision-threatening complications by Week 48
- Safety data revealed zero instances of intraocular inflammation during the study
- Company accelerating regulatory filing timeline for Biologics License Application
Shares of Kodiak Sciences (KOD) climbed to $22.75 after announcing positive trial results, building on a remarkable 656% surge over the previous 12 months, despite showing an 18.6% decline since the start of the current year.
The biotechnology company announced that Zenkuda (tarcocimab tedromer) successfully hit its primary goal in the GLOW2 Phase 3 clinical study focused on diabetic retinopathy treatment.
Data disclosed on March 26 demonstrated substantial superiority compared to the control arm across all measured parameters.
Within the study population, 62.5% of participants receiving Zenkuda demonstrated two or more steps of improvement on the diabetic retinopathy severity score (DRSS) at the 48-week mark. In contrast, only 3.3% of control group participants achieved this level of improvement.
The findings achieved statistical significance, successfully meeting the study’s primary objective with robust confidence levels.
Vision-Threatening Event Reduction
Beyond the primary measure, Zenkuda delivered an impressive 85% reduction in the likelihood of developing predefined vision-threatening events when compared to control through the 48-week evaluation period. These serious complications encompassed new or progressing proliferative diabetic retinopathy and center-involving diabetic macular edema.
A mere 2.4% of patients treated with Zenkuda experienced these complications, compared to 15.8% in the control arm.
For secondary measures, 13.7% of patients on Zenkuda demonstrated three or more steps of DRSS improvement, while the control group showed 0% achieving this threshold.
The data align closely with findings from the preceding GLOW1 trial, in which Zenkuda demonstrated an 89% reduction in sight-threatening complication risk.
GLOW2 served as the confirmatory trial to GLOW1, with an expanded enrollment that included individuals with proliferative diabetic retinopathy and mild diabetic macular edema.
Treatment protocol involved Zenkuda administration at study initiation, followed by doses at Week 4, Week 8, Week 20, and Week 44. By trial completion, all participants were maintained on a 6-month treatment interval.
Safety Data
Safety results proved favorable throughout the study. Zero cases of intraocular inflammation emerged, and investigators observed no instances of retinal vasculitis or occlusive retinal vasculitis.
Cataract adverse events occurred at a 2.3% rate in the Zenkuda group versus 1.6% in the control group — consistent with baseline expectations for diabetic retinopathy patient populations.
The GLOW2 trial enrolled patients taking GLP-1 receptor agonist therapies, mirroring real-world diabetic patient demographics. Approximately 46.1% of Zenkuda recipients and 42.4% of control participants were using GLP-1 medications.
Among Zenkuda patients on GLP-1 therapies, 60.0% achieved the primary endpoint, while 64.3% of those not using GLP-1 medications reached this milestone — a minimal variance suggesting limited influence of GLP-1 use on treatment outcomes.
The company announced plans to expedite its Biologics License Application filing schedule for Zenkuda following these encouraging GLOW2 results.
H.C. Wainwright maintains a Buy rating on KOD stock with a $38 price objective. UBS similarly holds a Buy rating with a $50 price target.
